How is insulin lispro different from regular human insulin?

It is absorbed faster and acts more quickly and for a shorter time, so it better matches the glucose rise after a meal. Randomized trials show improved postprandial control and, in type 1 diabetes, less severe hypoglycaemia.

What is the main risk of insulin lispro?

Hypoglycaemia (low blood glucose) is the principal risk and can become severe. Other effects include weight gain and injection-site reactions. Dosing must be individualised and supervised by a clinician.

Can I switch between insulin lispro and another insulin on my own?

No. Insulins differ in strength, onset and duration, and switching or mixing products without clinician guidance can cause dangerous high or low blood glucose. Any change should be made by your healthcare provider.

Is insulin lispro used with a long-acting insulin?

Often yes. It is commonly the mealtime (bolus) insulin in a basal-bolus regimen alongside a long-acting basal insulin, or delivered by pump, always under medical supervision.

EMA-approvedaka Humalog, Admelog

Insulin lispro — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin lispro (also known as Humalog) is a peptide catalogued under Hormones & Metabolic (Rapid-acting insulin analogue). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin lispro?

Insulin lispro (brand name Humalog and biosimilars) is a rapid-acting mealtime (bolus) human insulin analog approved by the FDA and EMA for adults and children with type 1 or type 2 diabetes.

It was the first insulin analog to reach market (FDA approval 1996) and is supported by a large body of randomized controlled trials and meta-analyses in humans.

It is a prescription drug, not a research chemical.

How does Insulin lispro work?

Reversing the B28-B29 amino acids of the insulin B-chain reduces self-association into hexamers, so lispro is absorbed from subcutaneous tissue faster than regular human insulin.

This gives a quicker onset and shorter duration of action that more closely matches the post-meal glucose rise.

What does the research say about Insulin lispro?

In a multicenter randomized trial in type 1 diabetes, lispro reduced postprandial glucose excursions and lowered the rate of hypoglycaemia compared with regular human insulin. ^[1]
A meta-analysis found insulin lispro significantly reduced the rate of severe hypoglycaemia in people with type 1 diabetes versus regular human insulin. ^[2]
A systematic review and meta-analysis reported that rapid-acting analogues such as lispro improved postprandial glucose control relative to regular human insulin in type 1 diabetes. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group — Anderson JH Jr et al., Diabetes 1997. (Randomized controlled trial)
[2] Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes — Brunelle BL et al., Diabetes Care 1998. (Meta-analysis)
[3] Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis — Davey P et al., Clinical Therapeutics 1997. (Meta-analysis)
[4] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. (Systematic review and meta-analysis)
[5] Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials — Sun D et al., Diabetes Technology and Therapeutics 2018. (Meta-analysis of RCTs)
[6] Safety of insulin analogs during pregnancy: a meta-analysis — Lv S et al., Archives of Gynecology and Obstetrics 2015. (Meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical practice lispro is injected subcutaneously shortly before (or with) meals as the bolus component of a basal-bolus regimen or via insulin pump.

This section is context only and is not dosing guidance; only a prescribing clinician can set an individual's insulin regimen.

Side effects & safety profile

Hypoglycaemia is the main and potentially serious risk, and it can be severe; risk rises with mismatched dosing, missed meals, exercise, or alcohol.

Other recognised effects include weight gain, injection-site reactions and lipohypertrophy, and rare hypersensitivity.

Dosing must be individualised by a clinician, and products should never be interchanged or mixed with other insulins without professional guidance.

Stacking & combinations

It is typically combined with a long-acting basal insulin (basal-bolus therapy) under medical supervision; it should not be self-combined with other agents outside a clinician's plan.

Finding Insulin lispro vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. It is an FDA- and EMA-approved prescription insulin analog (marketed as Humalog and biosimilars), first approved in 1996, for type 1 and type 2 diabetes. It is not an experimental or research-only compound.

References

[1] Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group — Anderson JH Jr et al., Diabetes 1997. PMID: 9000704. View sourceStudy: Randomized controlled trialLispro lowered postprandial glucose and reduced hypoglycaemia frequency versus regular human insulin in type 1 diabetes.
[2] Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes — Brunelle BL et al., Diabetes Care 1998. PMID: 9773738. View sourceStudy: Meta-analysisInsulin lispro significantly reduced the rate of severe hypoglycaemia compared with regular human insulin.
[3] Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis — Davey P et al., Clinical Therapeutics 1997. PMID: 9377611. View sourceStudy: Meta-analysisLispro improved postprandial control and was associated with fewer hypoglycaemic events than regular human insulin.
[4] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. PMID: 30622653. View sourceStudy: Systematic review and meta-analysisRapid-acting analogues improved postprandial glucose versus regular human insulin in type 1 diabetes.
[5] Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials — Sun D et al., Diabetes Technology and Therapeutics 2018. PMID: 30095984. View sourceStudy: Meta-analysis of RCTsCompared glycaemic and hypoglycaemia outcomes of premixed lispro programs versus glargine in type 2 diabetes.
[6] Safety of insulin analogs during pregnancy: a meta-analysis — Lv S et al., Archives of Gynecology and Obstetrics 2015. PMID: 25855052. View sourceStudy: Meta-analysisInsulin analogues including lispro showed a safety profile broadly comparable to human insulin in pregnancy.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.